Iovance Biotherapeutics Inc (NASDAQ: IOVA) is -52.70% lower on its value in year-to-date trading and has touched a low of $2.70 and a high of $14.23 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The IOVA stock was last observed hovering at around $3.50 in the last trading session, with the day’s loss setting it 0.0%.
Currently trading at $3.50, the stock is 6.51% and -3.63% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 8.4 million and changing 0.00% at the moment leaves the stock -53.04% off its SMA200. IOVA registered -72.00% loss for a year compared to 6-month loss of -68.30%.
The stock witnessed a 7.69% gain in the last 1 month and extending the period to 3 months gives it a -37.94%, and is -3.05% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.42% over the week and 9.37% over the month.
Iovance Biotherapeutics Inc (IOVA) has around 838 employees, a market worth around $1.17B and $164.07M in sales. Profit margin for the company is -226.84%. Distance from 52-week low is 29.63% and -75.40% from its 52-week high. The company has generated returns on investments over the last 12 months (-49.24%).
The EPS is expected to grow by 38.71% this year.
Iovance Biotherapeutics Inc (IOVA) Top Institutional Holders
The shares outstanding are 305.25M, and float is at 270.44M with Short Float at 26.39%.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 25.95 million shares valued at $208.12 million. The investor’s holdings represent 9.1113% of the IOVA Shares outstanding. As of 2024-06-30, the second largest holder is PERCEPTIVE ADVISORS LLC with 25.93 million shares valued at $207.98 million to account for 9.1052 of the shares outstanding. The other top investors are MHR FUND MANAGEMENT LLC which holds 24.0 million shares representing 8.4254% and valued at over $192.46 million, while BLACKROCK INC. holds 7.4522 of the shares totaling 21.23 million with a market value of $170.23 million.
Iovance Biotherapeutics Inc (IOVA) Insider Activity
The most recent transaction is an insider sale by Maynard Ryan D, the company’s Director. SEC filings show that Maynard Ryan D sold 50,000 shares of the company’s common stock on Nov 12 ’24 at a price of $10.06 per share for a total of $0.5 million. Following the sale, the insider now owns 7500.0 shares.
